Market Research Report: Cytiva



Company Overview



Name: Cytiva

Mission of the Company: _"At Cytiva, we envision a world in which access to life-changing therapies transforms human health. Our wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery."_

Founding and Founders: No information is available

Key People: Pierre-Alain Ruffieux, Chief Operating Officer

Headquarters: No information is available

Number of Employees: 15,000 associates

Revenue of the Company: No information is available

Primary Recognition:
  • Part of Danaher, a global science and technology leader.

  • Recognized for antibody purification.


Products



1. Bioprocessing Solutions
  • Description: End-to-end solutions supporting the journey from discovery to delivery.

  • Key Features:

  • Support for process development, intensification, and scaling.

  • Suitable for monoclonal antibodies, antibody variants, viral vectors, vaccines, recombinant proteins, cell and gene therapies, mRNA, and oligonucleotides.


2. Advanced Therapies
  • Description: Solutions for mRNA-LNP production, cell therapy production, gene therapy production, LNP therapeutics, therapeutic oligos.

  • Key Features:

  • Comprehensive support from research to manufacturing.

  • Tools to accelerate the production and commercialization process.


3. Diagnostics
  • Description: Tools to accelerate the development and commercialization of diagnostic assays and kits.

  • Key Features:

  • Support for lab-based molecular and immuno diagnostics, and point-of-care (POC) diagnostics.

  • Customized services for reagent characterization, assay development, and lyophilization.


4. Genomics
  • Description: Solutions for disease identification and the development of targeted therapies.

  • Key Features:

  • Optimization of DNA and RNA extraction.

  • Technologies for amplification, enrichment, sequencing, and single-cell sequencing.


5. Laboratory Filtration
  • Description: Filtration solutions for research labs, QC, and field applications.

  • Key Features:

  • Devices for analytical testing, cannabis sample prep, environmental monitoring, industrial applications, microbiology, and food and beverage testing.


6. Medical Filtration
  • Description: Filtration and membrane solutions for healthcare professionals, medical device manufacturers, and patients.

  • Key Features:

  • Anesthesia, intensive care ventilation, and surgical gas handling filtration.

  • IV filtration, OEM membrane filtration, and water filtration solutions.


7. Protein Research
  • Description: Workflow solutions from isolation and sequencing to sample preparation.

  • Key Features:

  • Protein purification systems and accessories.

  • Support for chromatography and biacore analysis.


Recent Developments



1. New Leadership:
  • Pierre-Alain Ruffieux joined as Chief Operating Officer.


2. Innovations and Releases:
  • Cytiva’s latest FlexFactory platform for oligonucleotides introduced at Ribobay Pharma.

  • Supor Prime sterilizing grade filters launched for improved filtration of high concentration biologics.


3. Support and Partnerships:
  • Collaboration with AGC Biologics to provide FlexFactory platforms for a new biomanufacturing facility in Japan.

  • Continued support for n-Lorem Foundation.


4. Sustainability Efforts:
  • Published the Global Biopharma Sustainability Review examining biopharma sustainability efforts.

  • Committed to Net Zero GHG emission reduction targets.


5. Product Developments:
  • New cell lines to meet the demands of viral vector manufacturing.

  • Innovative tools for next generation cell therapy manufacturing.


6. Customer Support:
  • Remote troubleshooting tools like OptiRun™ View aiding in customer support.


Summary



Cytiva is a global life sciences leader with a mission to transform human health through therapeutic advancements. They support biopharma across various stages of therapeutic development with innovative products, detailed process support, and a strong emphasis on sustainability. Recently, they have enhanced their filament technology, entered into strategic partnerships, and launched new products to sustain their market position in the rapidly evolving biopharma industry.